2025 HCPCS code J0641
(In Use) Effective Date: N/A Revision Date: N/A Drugs - Injection Drugs, Administered by Injection Feed
This HCPCS code represents 0.5 mg of levoleucovorin administered intravenously.
Modifiers may be applicable in certain situations, such as modifier JW if a portion of the drug is discarded.
Medical necessity for levoleucovorin is established when there's a high risk of methotrexate toxicity (e.g., high-dose methotrexate therapy) or when it's used as part of a combination therapy for colorectal cancer.Documentation must justify the need for levoleucovorin based on established clinical guidelines and the patient's specific condition.
The administering physician or qualified healthcare professional is responsible for accurate dosage, safe intravenous administration, and monitoring of the patient's response to levoleucovorin.This includes proper assessment of the patient's condition, selection of the appropriate dosage based on clinical guidelines, and management of potential adverse effects.Documentation of the administration, including the time, route, and amount administered, is crucial.
In simple words: This code is for a medicine called levoleucovorin, given through an IV to help lessen the harmful effects of other cancer drugs like methotrexate.It's also used with another medicine to treat colon cancer.
HCPCS code J0641 designates 0.5 mg of levoleucovorin administered via intravenous infusion or injection.Levoleucovorin is used to mitigate the toxic effects of high-dose methotrexate or folic acid antagonist overdoses. It's also used in conjunction with fluorouracil for treating metastatic colorectal cancer.This code is applied when no other code specifies this dosage. The clinical responsibility rests with the administering physician or qualified healthcare professional ensuring accurate dosage and safe intravenous administration.Dosage recommendations vary depending on the specific clinical indication, usually calculated based on body surface area (mg/m²).
Example 1: A patient receiving high-dose methotrexate for osteosarcoma requires levoleucovorin rescue therapy to prevent methotrexate toxicity. J0641 is used to code the intravenous administration of levoleucovorin., A patient with metastatic colorectal cancer is undergoing treatment with a combination of fluorouracil and levoleucovorin.J0641 is used to code the intravenous administration of the levoleucovorin component of the regimen., A patient experiences a severe adverse reaction to folic acid.The physician administers intravenous levoleucovorin to counter the adverse effects.J0641 is used to code the administration.
Complete medical record documentation is needed, including the indication for levoleucovorin (e.g., methotrexate toxicity, colorectal cancer treatment), the dosage administered, the route of administration (intravenous), date and time of administration, and any adverse reactions or complications.
** Always confirm the specific dosage of levoleucovorin administered and ensure accurate reporting.Consult the most current HCPCS codebook and payer guidelines for precise billing and coding instructions. If using a brand-name levoleucovorin, refer to specific codes for those products.
- Payment Status: Active
- Modifier TC rule: A Technical Component (TC) modifier is generally not applicable to J0641, as it represents the drug itself and not a technical component of a procedure.
- Specialties:Oncology, Hematology
- Place of Service:Inpatient Hospital, Outpatient Hospital, Ambulatory Surgical Center, Physician's Office